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Abstract 1 
Objectives  2 
To describe the treatment of hypertension in people with dementia and collate evidence on 3 
adverse health events whilst on treatment. 4 
Design   5 
A multi-centre prospective observational cohort study.  6 
Setting and Participants  7 
People with documented diagnoses of hypertension and dementia were recruited through 8 
memory clinics and general practice from eight sites in the UK. 9 
Methods  10 
The cohort was recruited between July 2013 and October 2014. Participants underwent 11 
face-to-face, standardised assessment of blood pressure (BP), activities of daily living, 12 
cognitive function, and medication use. Follow up was by monthly telephone interview for 6 13 
months to collate data on adverse health events. 14 
Results 15 
181 participants were recruited and 177 followed-up. 126 (70%) were female, mean age was 16 
82 (SD6.3) years, median Mini Mental State Examination score 23 (IQR18-26) and mean BP 17 
141/78 (SD22/12) mmHg. Antihypertensive drugs were prescribed in 157 (87%). Participants 18 
were prescribed a median of 1 (IQR1-2) antihypertensive medication. ACE-inhibitors and/or 19 
Angiotensin Receptor Blockers were the most frequently prescribed antihypertensives in 20 
63% of participants. Target BP was achieved in 58% (95% CI49% - 64%). Increasing 21 
number of antihypertensives was not associated with lower systolic or diastolic BP, or with a 22 
higher proportion of patients attaining target BP. Participants had 214 falls, three had a 23 
fracture, three developed symptomatic heart failure, four had cerebrovascular events and 24 
eight died. 25 
Conclusions and Implications 26 
In this population of people with mild dementia, participants were treated with standard 27 
antihypertensive medications in a similar proportion to the general population, with a similar 28 
proportion achieving target BP. The rate of adverse health events was higher than in 29 
randomised controlled trials of antihypertensives and raises reservations about the 30 
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assumptions underpinning antihypertensive treatment in people with dementia. These 31 
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Introduction 55 
International policies and guidelines stress the importance of the detection and treatment of 56 
hypertension, which is the most important cardiovascular risk factor with the greatest impact 57 
on mortality1-3.  High blood pressure is common amongst older adults. A reported 56.1% of 58 
community dwelling older people and 43.7% of care home residents have hypertension4. 59 
Prevalence increases with age5 and approximately 80% of those aged over 80 are 60 
hypertensive6. Multiple large scale randomised controlled trials, such as the Hypertension in 61 
the Very Elderly Trial (HYVET), have demonstrated health benefits from medications that 62 
lower blood pressure5,7 and increasingly guidelines are advocating lower and lower target 63 
blood pressures even amongst the oldest old8-10.  64 
Current guidance on hypertension advises that co-pathology should be taken into account 65 
when treatment decisions are made1. People with dementia were not included in the large 66 
scale Randomised Controlled Trials (RCTs) of antihypertensives. At present, there are no 67 
condition-specific recommendations for treating hypertension in people with dementia and 68 
the benefits of treatment are assumed to apply. Observational evidence, however, has 69 
suggested the benefits of blood pressure lowering may be attenuated by co-existing 70 
cognitive impairment. A cohort study of 1587 people over 75 years found higher systolic 71 
blood pressure to be associated with reduced mortality in people with cognitive and 72 
functional impairment11. The PARTAGE group found an association between increased 73 
mortality and a systolic BP below 130mmHg in care home residents taking two or more 74 
antihypertensives12. The Leiden 85+ study found an association between cognitive decline 75 
and low blood pressure in patients taking antihypertensives13; a finding replicated by 76 
Mossello and colleagues14.  77 
It is clear from the above that generic guidelines for management of hypertension may 78 
require some interpretation in patients with dementia. What is not clear is how the 79 
uncertainty surrounding treatment in this group influences practitioner decisions. It is 80 
possible, for instance, that those concerned about potential side effects of antihypertensives 81 
might advise against treatment or use less stringent target blood pressures15, while others 82 
might advocate tight blood pressure control16.  83 
There are limited data available on how people with cognitive impairment are affected by 84 
antihypertensive-associated adverse health events17. Medication side effects are commonly 85 
overlooked in dependent people with cognitive impairment18, raising the possibility of greater 86 
harm from adverse health events associated with antihypertensive therapy in people with 87 
dementia.  88 
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The aim of the Hypertension in Dementia (HinD) study, described in this paper, was to 89 
describe current practice regarding treatment of hypertension in people with dementia.  90 
Specific objectives were to (i) describe the proportion people with dementia and 91 
hypertension that are prescribed antihypertensives, (ii) to identify what class of 92 
antihypertensives are prescribed, (iii) to identify the proportion achieving target blood 93 
pressure, and (iv) to describe how often they report adverse health events during 6 months 94 
follow-up. By doing so the study aimed to provide more evidence for clinicians and patients 95 
to use in informed decision-making. 96 
Methods 97 
Study design 98 
The HinD study was an observational cohort study.  99 
Cohort 100 
The cohort involved a multi-centre prospective community-based cohort in the UK. Between 101 
July 2013 and October 2014, 181 individuals with recorded diagnoses of hypertension and 102 
dementia were recruited via GP practices and memory clinics from 8 sites. All participants 103 
had an informant and where they lacked capacity to consent consultee advice was sought 104 
regarding participation in the study. After informed consent or consultee advice was 105 
obtained, participants and informants underwent a face-to-face standardised assessment 106 
involving assessment of blood pressure, activities of daily living (ADLs), cognitive function, 107 
and medication use. Participants were followed up with monthly telephone interviews for 6 108 
months to collect information on adverse health events. (Ethical approval was obtained from 109 
NRES Committee East Midlands - Nottingham 1 REC ref. 13/EM/0099 and Scotland A 110 
REC ref. 14/SS/0035)  111 
Selection criteria 112 
Individuals with documented diagnoses of hypertension and dementia were potentially 113 
eligible for this study. In those recruited through general practice, practice databases were 114 
searched for individuals coded as having these two conditions on the practice database. In 115 
those recruited through memory services, clinics used recorded medical histories of 116 
hypertension and dementia to identify potential participants. Hypertension and dementia 117 
diagnoses were not re-evaluated during screening for this study and prescription of 118 
antihypertensive medication was not used to identify people with hypertension. 119 
 120 
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Blood pressure 122 
Researchers measured blood pressure using a validated automatic BP machine (OMRON 123 
M6 HEM-7211-E) with an appropriate cuff size after 10 minutes of rest when seated.  The 124 
blood pressure one minute after standing was then measured. Postural hypotension was 125 
defined as a drop of more than 20mmHg in systolic blood pressure or of 10mmHg in diastolic 126 
blood pressure. 127 
Cognitive assessment and dependency for ADLs 128 
Cognitive function was assessed using the Mini-Mental State Examination (MMSE)19. 129 
Dependency for activities of daily living was evaluated using the modified Barthel Index20. 130 
Comorbidity 131 
Participants and informants were asked about their medical diagnoses at baseline interview 132 
and these were confirmed by reference to medical records. 133 
Medical events 134 
Participants and informants were contacted every week for four weeks and then monthly for 135 
a further 5 months. A structured telephone interview with the participant and/or informant 136 
was used to collect data on falls, falls with fractures, new cardio- or cerebrovascular events 137 
(self-reported myocardial infarction, stroke, TIA, heart failure), or death.  138 
Planned statistical analysis 139 
Descriptive statistics were used to describe the study population and its antihypertensive 140 
treatment and adverse health events in detail. The rate of reported adverse health events 141 
over the duration of the study was transformed into the rate per 1000patientyears and 95% 142 
confidence interval estimates were calculated. Differences between GP and memory clinic 143 
recruits, between those achieving and those not achieving target BP, and between those 144 
taking and not taking antihypertensive agents were explored using: the t-test for continuous 145 
and normally distributed variables; the Mann-Whitney U test for continuous and non-normally 146 
distributed or ordinal variables and the Chi-Squared test for categorical variables. 147 
Association between number of antihypertensives and blood pressure and achievement of 148 
target blood pressure was tested using regression analysis. 149 
Results 150 
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Study population 151 
1585 eligible individuals with diagnoses of hypertension and dementia were invited to 152 
participate in the study via mail sent to clinic lists from GP practices and memory clinics from 153 
8 sites within the UK. 181 individuals were recruited: 86 from GP practices, 95 from memory 154 
clinics. Of these 181 individuals, one withdrew before baseline assessment could be 155 
completed and a further three withdrew before follow-up commenced, leaving 177 to enter 156 
follow up (Figure 1).  157 
People recruited via GP were more likely to have fallen (30% vs 16% p=0.021), took fewer 158 
antihypertensives (median 1 (IQR1-2) vs 2 (IQR 1-2) p=0.008), had more medical diagnoses 159 
(median 5.5 (IQR 4-8) vs 4 (3-5) p<0.001), and were more dependent for basic ADLs 160 
(Barthel median 19 (IQR 14.75-20) Vs 20 (IQR 17-20) p=0.028) compared to those recruited 161 
via memory clinics. 162 
 163 
Figure 1 Participant flow diagram 164 
 165 
At baseline 126 (70%) were female, mean age was 82 years (SD 6.3), and median MMSE 166 
score was 23 (IQR 18-26). Alzheimer’s dementia was the most common dementia diagnosis 167 
in 101 (56%), followed by vascular dementia 36 (20%), mixed dementia 23 (13%) and others 168 
20 (11%). There were a median of 5 (IQR 3-7) medical diagnoses per participant. Diabetes 169 
mellitus was the most common problem (35 (19%)) while previous stroke and myocardial 170 
infarction were also frequently reported (28 (16%), 23 (13%) respectively). The baseline 171 
variables of the HIND population are summarised in table 1. 172 
Table 1. HIND population baseline variables 173 
 174 
Blood pressure and treatment 175 
High blood pressure was treated in 157 (87% (95% CI 82% - 92%)); 23 (13%) were taking 176 
no agents, 79 (44%) were taking one, 50 (28%) were taking two, 20 (11%) were taking three, 177 
6 (3%) were taking four and 2 (1%) were taking five agents. ACEi/ARBs were the most 178 
frequently prescribed antihypertensive (63%), followed by calcium channel blockers (37%), 179 
beta-blockers (34%) and diuretics (23%). An average blood pressure of 141/78 (SD 22/12) 180 
was recorded. Increasing number of antihypertensives was not associated with lower blood 181 
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pressure (systolic blood pressure R2=0.008 P=0.248, diastolic blood pressure R2=0 182 
P=0.907) see Table 2. 183 
Target blood pressure (as defined by NICE 2011 guidance1) was achieved in 58% (95% CI 184 
49% - 64%) of those on treatment. Increasing numbers of antihypertensives were not 185 
associated with a higher proportion of participants having a blood pressure at or below their 186 
specified target (p= 0.952) (table 2). 187 
 188 
Table 2 The number of antihypertensive agents prescribed and mean blood pressure and 189 
proportion achieving target blood pressure. 190 
 191 
Postural blood pressure 192 
Postural blood pressures were measured in 174 individuals at baseline and were omitted in 193 
6 where participants were unable to stand. 19 (11%) participants had a drop in blood 194 
pressure sufficient to meet the criteria for orthostatic hypotension. Orthostatic hypotension 195 
was more prevalent in those not prescribed antihypertensives (6 (26%) Vs 13 (8.6%) 196 
P=0.009).   197 
Follow up 198 
177 participants entered follow up of whom 155 were taking at least one antihypertensive. Of 199 
those on treatment during 6 months follow up, 71 participants (46%) reported at least one fall 200 
and 30 (19%) two or more. In total 214 falls were sustained; a rate of 2760 falls per 1000 201 
patient-years. Three participants (2%) sustained a fracture (41 per 1000 patient-years) as a 202 
result of falling, three (2%) experienced five episodes of heart failure (65 (95% CI 58-71) per 203 
1000 patient-years), four (3%) experienced six strokes / TIAs (77 (95% CI 70-84) per 1000 204 
patient-years) and eight (5%) participants died (103 (95%CI 95-111) per 1000 patient-years).  205 
Discussion 206 
In this study of people with mild dementia and a diagnosis of hypertension, high blood 207 
pressure was treated in the majority of participants and standard antihypertensive 208 
medication was used. Target blood pressure was achieved in just over half of participants 209 
irrespective of the number of antihypertensives prescribed. The majority of those not 210 
prescribed antihypertensives had blood pressure readings within the target range. 211 
Presumably these individuals had become normotensive having previously been 212 
8 
Hypertension in people with dementia 
hypertensive or had been erroneously coded. The study population largely had mild 213 
dementia, but experienced multiple adverse health events during the six month follow up 214 
period with falls being the most common. 215 
The study recruited participants from a variety of settings and geographical locations so its 216 
findings are likely to be applicable across the whole of the UK. The most important limitation 217 
affecting the study was that the recruitment strategy selected a study population with mild 218 
dementia, limiting generalisability of the findings to this group.  219 
A systematic review of historical observational studies of the treatment of hypertension in 220 
people with dementia 18 found that 73% were on at least one antihypertensive. In the current 221 
study treatment rates were higher at 87% (95% CI 82% - 92%), which is in keeping with the 222 
findings of a survey of the general population (Health Survey for England 2011) where the 223 
reported treatment rate was also 87%21. The higher treatment rate, than that identified by the 224 
review, may be an effect of the timing of the study, or because the HinD population were 225 
mildly cognitively impaired and hence similar to the general population. The proportion 226 
achieving target blood pressure (58%) was similar to that reported in both the review (55%)18 227 
and Health Survey (52%)21.  The average blood pressure was similar to that achieved in 228 
randomised controlled trials such as HYVET (140/72 (HYVET) vs 141/78 (HinD))10.The 229 
Health Survey found that ACEi/ARBs were the most frequently prescribed class22 – the 230 
same as in the HinD study. However, the systematic review identified diuretic 231 
antihypertensives as the most frequently prescribed class (64%), while calcium channel 232 
blockers (43%), ACEi/ARBs (42%) and β-blockers (42%) were less commonly prescribed 233 
perhaps reflecting historic prescribing trends18.  234 
The HinD population experienced multiple adverse health events including 214 falls, of 235 
which 3 resulted in fractures, and one in twenty dying during the 6 month follow-up period. 236 
The incidence of falls (2760 falls per 1000 patient-years) was similar to that reported by Allan 237 
and colleagues in another UK cohort study of people with mild to moderate dementia due to 238 
Alzheimer’s disease (2486 per 1000 patient-years) and vascular disease (3135 per 1000 239 
patient years)23. The rate of falls  was higher than has been reported in non-cognitively 240 
impaired older people (1023 per 1000 patient-years)23 and in community dwelling older 241 
women (1003 per 1000 patient-years)24. The fracture rate (41 per 1000 patient-years) was 242 
higher than that reported in those aged 80-85 in the Rotterdam Study (20 per 1000 patient-243 
years men, 30 per 1000 patient years for women). This is in keeping with other groups’ 244 
findings that falls and fractures are more common in people with cognitive impairment25-27. 245 
The rates of events such as heart failure (65 (95% CI 58-71) per 1000 patient-years), stroke 246 
(77 (95% CI 70-84) per 1000 patient-years) and death (103 (95%CI 95-111) per 1000 247 
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patient-years) were higher than those reported in trials such as HYVET (heart failure 5.3 per 248 
1000 patient-years, stroke 12.4 per 1000 patient-years, death 47.2 per 1000 patient-years 249 
10). This may reflect the higher conventional vascular risk within the HinD population where 250 
the prevalence of comorbidities such as diabetes and ischaemic heart disease was higher10 251 
at baseline. Previous observational data have raised the possibility that the effect of blood 252 
pressure lowering may be attenuated in the presence of co-existing cognitive impairment. 253 
The Milan Geriatrics 75+ cohort study found that in participants with Mini-Mental State 254 
Examination scores indicating cognitive impairment and ADL dependence, a higher systolic 255 
blood pressure was associated with reduced mortality11. The data from HIND therefore 256 
aligns with data from generic longitudinal observational cohort studies which suggest that 257 
populations recruited by RCTs, such as HYVET, were not fully representative of the patterns 258 
of comorbidity and adverse outcomes seen in the real world.  In HIND, as in the Milan-65+ 259 
and PARTAGE studies, both were more common.  260 
Conclusion and implications 261 
Participants in this study had their blood pressure treated with standard antihypertensive 262 
medications. Their blood pressure was treated in a similar proportion to the general 263 
population and a similar proportion achieved target blood pressure. This suggests that 264 
clinicians currently do not regard this group as being sufficiently different from patients 265 
without dementia to recommend specific treatment approaches. The higher rate of adverse 266 
health events experienced by this population compared to the findings of the large scale 267 
randomised controlled trials may just reflect the relative robustness of a randomised 268 
controlled trial population. However, it does raise the possibility that treatment of 269 
hypertension in people with dementia may be associated with greater harm. Clinicians must 270 
understand the caveats attached to treatment in this patient group – it is not clear that they 271 
currently do so, or if they do, that this understanding changes practice. 272 
These discussions are, at present, stymied by the limitations of observational data and in 273 
particular by the largely mildly impaired nature of participants. A randomised controlled trial 274 
examining the risk to benefit ratio of antihypertensives in people with dementia is one 275 
possible way forward but could, in practice, be very difficult to conduct. In the absence of an 276 
RCT, further observational data are required so that those writing guidelines can give 277 
appropriate consideration to the safest approach to treatment in this vulnerable group of 278 
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